RET and lung carcinoma: Vandetanib, sunitinib, sorafenib, lenvatinib, ponatinib, and cabozantinib are all multi-targeted kinase inhibitors that target RET. Activity has been seen in RET-positive lung cancer patients with cabozantinib and vandetinib, and multiple trials are ongoing in this population with a recent halt in a ponatinib study for safety concerns (24, 25).